SOM Webcast: Expert insights on Huntington’s Disease and SOM3355
WATCH NOW →
We are a cutting-edge, late-stage clinical development company pioneering an Artificial Intelligence (AI) platform for drug discovery since 2010 dedicated to rare CNS disorders.
We are a cutting-edge, late-stage clinical development company pioneering an Artificial Intelligence (AI) platform for drug discovery since 2010 dedicated to rare CNS disorders.
Every patient and families' journey with rare CNS disorders is deeply personal, marked by courage, uncertainty, and an enduring sense of hope. At SOM Biotech, we stand beside those facing the challenges of a rare disease and the limited treatments available today. They are the inspiration behind our mission—driving us to innovate with purpose and to pursue new therapies that offer hope throughout every step of their journey.
LEARN MORE →Our AI-driven platform has demonstrated a high clinical predictivity, with two compounds that achieved positive Phase 2 clinical results. This has enabled accelerated pathways for new treatments where there continues to be clinical unmet needs.
LEARN MORE →Our AI-driven platform has demonstrated a high clinical predictivity, with two compounds that achieved positive Phase 2 clinical results. This has enabled accelerated pathways for new treatments where there continues to be clinical unmet needs.
LEARN MORE →
We are advancing a pipeline targeting rare CNS disorders with profound unmet needs, anchored by a lead asset in late clinical development and ready to enter Phase 3 for the symptomatic treatment of Huntington’s disease.
LEARN MORE →